“We need all the capital we can get our hands on," the company states.

The move follows promising but early data presented at ASCO.

Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.

The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.

AstraZeneca bags three of the month’s four oncology approvals.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.